Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
1.
Med. intensiva (Madr., Ed. impr.) ; 44(2): 80-87, mar. 2020. graf, tab
Artigo em Espanhol | IBECS | ID: ibc-188656

RESUMO

Objetivos: Recopilar la información publicada sobre estabilidad de los fármacos usados en el paciente crítico, evaluar la calidad de los datos publicados y generar una tabla de compatibilidad con información actualizada. Diseño: 1) Se realizó una búsqueda sistemática en las bases de datos Medline, Stabilis, Handbook on Injectable Drugs y Micromedex, para completar y actualizar la información disponible. Se incluyeron los estudios publicados entre 1990 y 2017 redactados en inglés, español y francés; 2) se analizó la calidad de los artículos según los criterios indicados en las guías de práctica para estudios de estabilidad; 3) se construyó una tabla de compatibilidades con los datos hallados para las combinaciones binarias de 44 fármacos de uso frecuente en unidades de cuidados intensivos (UCI). Ámbito: UCI de hospitales españoles e internacionales. Resultados: La revisión sistemática incluyó 29 artículos (27 originales y 2 revisiones). Ningún estudio cumplió todos los criterios de calidad establecidos, aunque el 93% garantizaba una correcta reproducibilidad. La tabla final aporta datos de compatibilidad fisicoquímica de 475 de las 945 combinaciones posibles (50,3%), de las cuales 366 (77,1%) son compatibles y 80 (16,8%) son incompatibles. Conclusiones: Se proporciona una actualización de las compatibilidades entre los fármacos habitualmente empleados en las UCI, con la intención de contribuir a la administración segura de medicamentos en pacientes críticos


Objectives: To gather all published information about the stability of drugs commonly used in Intensive Care Units (ICU); evaluate the methodology of published data; and generate a compatibility table. Design: i) A systematic review was conducted searching the following databases: Medline, Stabilis, Handbook of Injectable Drugs and Micromedex. Articles published from 1990 to 2017 in English, Spanish and French were included. ii) Article quality was analyzed according to the stability studies practice guidelines. iii) A compatibility table was produced with data for 44 binary combinations of drugs frequently used in the ICU. Scope: Spanish and international hospital ICU. Results: The systematic review included 29 studies (27 originals, 2 reviews). None of the included studies followed all the methodological requirements. However, 93% guaranteed correct reproducibility. Accordingly, drug stability knowledge was available for 50.3% of the studied admixtures, in which 77.1% of the binary combinations proved compatible and 16.8% proved incompatible. Conclusions: This review provides new reliable evidence about the physicochemical stability of drugs commonly used in the critical care setting. The study contributes to the safe administration of intravenous drugs in critical patients with a view to avoiding adverse events in this frail population


Assuntos
Humanos , Unidades de Terapia Intensiva , Estabilidade de Medicamentos , Preparações Farmacêuticas/química , Combinação de Medicamentos , Incompatibilidade de Medicamentos , Infusões Intravenosas/métodos , Preparações Farmacêuticas/administração & dosagem
2.
Med Intensiva (Engl Ed) ; 44(2): 80-87, 2020 Mar.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-30262380

RESUMO

OBJECTIVES: To gather all published information about the stability of drugs commonly used in Intensive Care Units (ICU); evaluate the methodology of published data; and generate a compatibility table. DESIGN: i) A systematic review was conducted searching the following databases: Medline, Stabilis, Handbook of Injectable Drugs and Micromedex. Articles published from 1990 to 2017 in English, Spanish and French were included. ii) Article quality was analyzed according to the stability studies practice guidelines. iii) A compatibility table was produced with data for 44 binary combinations of drugs frequently used in the ICU. SCOPE: Spanish and international hospital ICU. RESULTS: The systematic review included 29 studies (27 originals, 2 reviews). None of the included studies followed all the methodological requirements. However, 93% guaranteed correct reproducibility. Accordingly, drug stability knowledge was available for 50.3% of the studied admixtures, in which 77.1% of the binary combinations proved compatible and 16.8% proved incompatible. CONCLUSIONS: This review provides new reliable evidence about the physicochemical stability of drugs commonly used in the critical care setting. The study contributes to the safe administration of intravenous drugs in critical patients with a view to avoiding adverse events in this frail population.


Assuntos
Combinação de Medicamentos , Interações Medicamentosas , Unidades de Terapia Intensiva , Preparações Farmacêuticas/química , Incompatibilidade de Medicamentos , Humanos , Infusões Intravenosas/métodos , Erros de Medicação/prevenção & controle , Preparações Farmacêuticas/administração & dosagem , Reprodutibilidade dos Testes
5.
Med. intensiva (Madr., Ed. impr.) ; 37(3): 185-200, abr. 2013. tab
Artigo em Espanhol | IBECS | ID: ibc-113798

RESUMO

Pseudomonas es un patógeno frecuente en las unidades de pacientes críticos y puede ser causa de shock séptico y de fallo renal. Es fundamental en estos pacientes instaurar un tratamiento antibiótico precoz y a dosis adecuadas. La disfunción renal aguda es también habitual en pacientes críticos. En aquellos que necesitan depuración extrarenal, las técnicas continuas de depuración extrarenal (TCDE) son una alternativa a la hemodiálisis intermitente y es necesario tener en cuenta que muchos antibióticos se eliminan de forma sustancial por las TCDE. El objetivo de esta revisión es analizar la evidencia clínica disponible sobre el comportamiento farmacocinético y las recomendaciones posológicas de los principales grupos de antibióticos empleados en el tratamiento de infecciones por Pseudomonas spp. en pacientes críticos sometidos a técnicas continuas de depuración extrarenal (AU)


Critically ill patients are often affected by infections produced by Pseudomonas, which can be a cause of sepsis and renal failure. Early and adequate antibiotic treatment at correct dosage levels is crucial. Acute kidney injury is also frequent in critically ill patients. In those patients who require renal replacement therapy, continuous techniques are gaining relevance as filtering alternatives to intermittent hemodialysis. It must be taken into account that many antibiotics are largely cleared by continuous renal replacement therapies (CRRT).The aim of this review is to assess the clinical evidence on the pharmacokinetics and dosage recommendations of the main antibiotic groups used to treat Pseudomonas spp. infections in critically ill patients subjected to CRRT (AU)


Assuntos
Humanos , Pseudomonas/patogenicidade , Infecções por Pseudomonas/tratamento farmacológico , Antibacterianos/administração & dosagem , Injúria Renal Aguda/complicações , Taxa de Depuração Metabólica , Cuidados Críticos/métodos , Terapia de Substituição Renal
6.
Med Intensiva ; 37(3): 185-200, 2013 Apr.
Artigo em Espanhol | MEDLINE | ID: mdl-22475763

RESUMO

Critically ill patients are often affected by infections produced by Pseudomonas, which can be a cause of sepsis and renal failure. Early and adequate antibiotic treatment at correct dosage levels is crucial. Acute kidney injury is also frequent in critically ill patients. In those patients who require renal replacement therapy, continuous techniques are gaining relevance as filtering alternatives to intermittent hemodialysis. It must be taken into account that many antibiotics are largely cleared by continuous renal replacement therapies (CRRT). The aim of this review is to assess the clinical evidence on the pharmacokinetics and dosage recommendations of the main antibiotic groups used to treat Pseudomonas spp. infections in critically ill patients subjected to CRRT.


Assuntos
Injúria Renal Aguda/complicações , Injúria Renal Aguda/terapia , Antibacterianos/administração & dosagem , Infecções por Pseudomonas/complicações , Infecções por Pseudomonas/tratamento farmacológico , Terapia de Substituição Renal , Humanos , Meropeném , Terapia de Substituição Renal/métodos , Tienamicinas/administração & dosagem
11.
Emergencias (St. Vicenç dels Horts) ; 21(4): 276-282, jul.-ago. 2009. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-61671

RESUMO

Objetivo: Los antídotos constituyen una medida básica para el tratamiento de determinadas intoxicaciones agudas. El objetivo de este estudio es describir la utilización de antídotos en la práctica clínica de los servicios de urgencias (SU) de dos hospitales y precisar el coste que representa la terapéutica antidótica respecto al coste global del tratamiento farmacológico del enfermo intoxicado. Método: Estudio prospectivo y descriptivo, diseñado para conocer la utilización y el coste farmacéutico de los antídotos administrados en los SU de dos hospitales universitarios. El periodo de recogida de datos fue de marzo a noviembre de 2006. Las variables evaluadas fueron el uso, la idoneidad y la eficacia del antídoto, así como el coste del tratamiento farmacológico (antídotos y medicación concomitante).Resultados: Se realizaron 228 administraciones de 14 antídotos diferentes a 184 pacientes(el 8,7% de las intoxicaciones agudas atendidas durante el periodo de estudio).Se consideró que el uso del antídoto había estado justificada para intentar revertir los efectos del tóxico en el 85,3% de los casos, correspondientes a 10 de los 14 antídotos utilizados. Tras la administración, se consiguieron los efectos esperados en el 73,9% de los casos. El 16% de las administraciones de flumazenilo y el 4% de las de naloxona no estuvieron bien indicadas. Se observaron reacciones adversas en el 6,5% de las administraciones. El coste que representaron los antídotos respecto al coste global del tratamiento farmacológico de los pacientes intoxicados fue del 81,97%, cifra que supone el1,1% del gasto farmacológico total del SU durante el periodo de estudio. Conclusiones: La indicación de los antídotos en urgencias fue globalmente adecuada, pero no exenta de efectos secundarios. El flumazenilo y la naloxona fueron utilizados con excesiva frecuencia. El coste económico que representa el tratamiento con antídotos es muy bajo (AU)


Background and objectives: Antidotes are basic resources among the options available for treating certain types of acute intoxication. The aim of this study was to describe the use of antidotes in the emergency departments of 2hospitals and to determine the cost of using these drugs in the context of the overall treatment of patients who have been poisoned. Material and methods: Prospective descriptive study of the use and cost of antidotes administered in the emergency departments of 2 university teaching hospitals. Data were collected from March through November 2006. Variables assessed were the use, suitability, and efficacy of each antidote, and the total expenditure on drugs (antidotes plus other medications).Results: Antidotes were administered 228 times to 184 patients (8.7% of acute intoxications attended during the study period). Use of the antidote was considered justified in the attempt to reverse the effect of poisoning in 85.3% of the cases, corresponding to 10 of the 14 antidotes used. The expected reversal was achieved in 73.9% of the cases. Use was inappropriate in 16% of the administrations of flumazenil and 4% of the administrations of naloxone. Adverse events were recorded in 6.5% of the cases in which antidotes were used. Expenditure on antidotes accounted for 81.97% of the total amount spent on the pharmacologic treatment of poisoned patients and 1.1% of the amount spent on all drugs used in emergency department care during the study period. Conclusions: The use of antidotes in the emergency department is largely appropriate but not free of side effects. Flumazenil and naloxone were used too often. Expenditure on antidotes is very low (AU)


Assuntos
Humanos , Serviços Médicos de Emergência/economia , Tratamento de Emergência/economia , Antídotos/economia , /estatística & dados numéricos , Intoxicação/tratamento farmacológico , Custos de Medicamentos/estatística & dados numéricos
12.
Farm. hosp ; 32(4): 199-207, jul.-ago. 2008. ilus, tab
Artigo em Espanhol | IBECS | ID: ibc-105234

RESUMO

Objetivo: Evaluar las desviaciones de dosificación de 3 antibióticos betalactámicos eliminados por vía renal (meropenem, piperacili na/tazobactam y cefepima) mediante la comparación de 2 fórmulas de predicción de función renal, Cockroft-Gault (CG) y Modification of Diet in Renal Disease (MDRD), con el aclaramiento de creatinina en orina de 24h (ClCr24h) como método de referencia. Método: Las 125 muestras de 61 pacientes (cada una con sus valores de CG, MDRD y ClCr24h) de una unidad de cuidados intensivos (UCI) se clasificaron en los 5 estadios definidos por la National Kidney Foundation (NKF) en función del ClCr24h. Se estudiaron las discrepancias de dosificación de cada antibiótico según CG o MDRD en referencia al ClCr24h por acuerdo porcentual e índice kappa ponderado. En cada estadio de NKF se cuantificaron las diferencias de dosificación diaria (¿ = DosisCG-DosisClCr24h; ¿ = Dosis MDRD DosisClCr24h) y el porcentaje de muestras con discrepancias de dosificación por CG y MDRD en referencia al ClCr24h. Resultados: En ningún caso se observaron diferencias estadísticamente significativas entre ambas fórmulas con respecto al ClCr24h, obteniendo grados de concordancia buenos. Los porcentajes de desviaciones oscilaron del 15,2% al 28% y ocurrieron mayoritariamente por infradosificación en los estadios 1 y 2, y por sobredosificación en los estadios 4 y 5. Conclusiones: Las dos predicciones de función renal en pacientes de la UCI pueden ser empleadas indistintamente para la dosificación de betalactámicos, aunque la de CG es la más sencilla (AU)


The impact of different renal function measuring methods on the dosages of meropenem, piperacillin/tazobactam and cefepime in critically ill patients Objective: Assesment of dosage deviations of three â-lactam antibiotics eliminated through the kidneys (meropenem, piperacillin/tazobactam and cefepime) by comparison of two prediction formulae, Cockroft-Gault (CG) and Modification of Diet in Renal Disease (MDRD)with 24 h urinary creatinine clearance (CrCl24h), as a reference method. Method: 125 samples of 61 critically ill patients (each one with CG,MDRD y CrCl24hvalues) were classified in one of the five stages of the National Kidney Foundation (NKF) according to CrCl24h. Dosage discrepancies for each antibiotic based on CG y MDRD were studied in reference to CrCl24hby percentage agreement and weighted kappa. At each of the NKF stages, daily dosage differences (∆=DosisCG-DosisCrCl24h;∆=DosisMDRD-DosisCrCl24h) and percentage of samples with dosage discrepancies by CG and MDRD in reference to CrCl24h were calculated. Results: There were no statistically significant differences between the two prediction formulae in respect to CrCl24h, achieving good degrees of concordance. Deviation percentages fluctuated between15.2% and 28% and occurred mainly by under dosing on stages 1and 2 and by overdosing on stages 4 and 5.Conclusions: The two renal function prediction formulae can be indistinctly used to optimize the â-lactam antibiotics dose regimen, CGbeing the easiest one (AU)


Assuntos
Humanos , Testes de Função Renal/métodos , Taxa de Filtração Glomerular , Piperacilina/administração & dosagem , Antibacterianos/administração & dosagem , beta-Lactamas/administração & dosagem , Creatinina/urina , Estado Terminal
13.
Farm Hosp ; 32(4): 199-207, 2008.
Artigo em Espanhol | MEDLINE | ID: mdl-19128727

RESUMO

OBJECTIVE: Assesment of dosage deviations of three ss-lactam antibiotics eliminated through the kidneys (meropenem, piperacillin/tazobactam and cefepime) by comparison of two prediction formulae, Cockroft-Gault (CG) and Modification of Diet in Renal Disease (MDRD) with 24 h urinary creatinine clearance (CrCl(24h)), as a reference method. METHOD: 125 samples of 61 critically ill patients (each one with CG, MDRD y CrCl(24h) values) were classified in one of the five stages of the National Kidney Foundation (NKF) according to CrCl(24h). Dosage discrepancies for each antibiotic based on CG y MDRD were studied in reference to CrCl(24h) by percentage agreement and weighted kappa. At each of the NKF stages, daily dosage differences (Delta=DosisCG-DosisCrCl(24h); Delta=DosisMDRD-DosisCrCl(24h)) and percentage of samples with dosage discrepancies by CG and MDRD in reference to CrCl(24h) were calculated. RESULTS: There were no statistically significant differences between the two prediction formulae in respect to CrCl(24h), achieving good degrees of concordance. Deviation percentages fluctuated between 15.2% and 28% and occurred mainly by underdosing on stages 1 and 2 and by overdosing on stages 4 and 5. CONCLUSIONS: The two renal function prediction formulae can be indistinctly used to optimize the ss-lactam antibiotics dose regimen, CG being the easiest one.


Assuntos
Antibacterianos/administração & dosagem , Antibacterianos/urina , Cefalosporinas/administração & dosagem , Cefalosporinas/urina , Estado Terminal , Testes de Função Renal/métodos , Tienamicinas/administração & dosagem , Tienamicinas/urina , Cefepima , Humanos , Meropeném , Ácido Penicilânico/administração & dosagem , Ácido Penicilânico/análogos & derivados , Ácido Penicilânico/urina , Piperacilina/administração & dosagem , Piperacilina/urina , Combinação Piperacilina e Tazobactam , Estudos Retrospectivos
16.
Farm Hosp ; 29(1): 55-63, 2005.
Artigo em Espanhol | MEDLINE | ID: mdl-15773803

RESUMO

Severe sepsis is a high prevalent disease at Intensive Care Units with no specific treatment till recently. Several clinical trials show low serum levels of activated protein C in this kind of patients. Recently, drotrecogin alfa (activated), a recombinant human activated protein C, has been approved in Spain for severe sepsis treatment in addition to the best patient care. Protein C (activated) has antithrombotic, profibrinolitic an antiinflamatory properties. So far, Prowess (phase 3 trial) is the most important clinical trial conducted with drotrecogin alfa (activated) at the moment. It demonstrates not only its efficacy and safety, but also a 19.4% reduction in the relative risk of death. Nevertheless, it is difficult to decide which patients would be candidate for this new therapy due to its lack of experience, high cost and the risk-benefit relationship. This review attempts to provide an overview about this new hospital drug.


Assuntos
Sepse/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...